Role of FDG PET/CT in Patients With Metastasis of Unknown Origin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

73 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-31

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluatation of the role of F18FDG-PET/CT in patients with metastases of unknown origin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

CUP Project PET/CT

NCT01469026

Metastasising Cancer of Unknown Primary

UNKNOWN PHASE4

Dynamic F-DOPA PET for Differential Diagnosis Between Recurrence and Radionecrosis of Brain Metastasis

NCT05762172

Brain Metastases Radiation Necrosis

COMPLETED NA

The Role of 18F-FDG-PET/CT Scan in Lung Cancer Patients

NCT04395651

Lung Cancer

UNKNOWN

Role of Positron Emission Tomography in Detecting Primary Tumor in Cases of Metastases of Unknown Origin

NCT06086652

Metastasis of Unknown Origin

UNKNOWN

PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy

NCT00019565

Unspecified Adult Solid Tumor, Protocol Specific

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cancer of unknown primary origin (CUP) includes a cluster of heterogeneous tumors that have exceptional clinical features: it is defined as early apparent metastatic disease with no recognizable primary site at the time of presentation. The incidence of CUP ranges around 2% of all new cancer diagnoses.

The work up list of CUP include; a biopsy proven malignancy, a detailed physical examination, many laboratory, radiological and endoscopy. However, these investigations may be costly time-consuming and may eventually fail to detect the site of the primary malignant tumor in the majority of patients. In this context, positron-emission tomography (PET) combined with computed tomography (PET/CT), using the radiotracer 18F fluoro- 2-deoxyglucose (FDG) is an alternative, non-invasive imaging modality with accurate diagnostic performance. It considered good tool for diagnosis of patients with CUP . The basis for use of FDG as radiotracer for PET imaging in CUP depends on the fact that most of the malignant cancer phenotypes show an increased glucose metabolism rate.

Failure to identify the primary tumor hampers optimization of management planning, which in turn may adversely influence patient prognosis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metastasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PET/CT

Patient preparation: Patients will fast for 4 - 6 h before PET scanning to optimize the blood sugar level to 160mg/dl. F-18 FDG dose was 0.14 mCi/kg and injected via intravenous route. During the uptake phase of 18F-FDG patients will be rested in a quite warm room.

Procedure:

All PET-CT studies will be done at the nuclear medicine unit in Assuit University Hospital.

PET-CT images will be interpreted at a workstation equipped with fusion software that offers multi-planar reformatted images and enables display of the PET images, CT images, and fused PET/CT images.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with age more than 18 years presented with either pathologically proved metastases of unknown primary or
* Patients with clinico-radiological suspicious of having metastases.

Exclusion Criteria

* • Age below 18 years,

* patients with pathologically proved primary tumor,
* Patients suffering from advanced disease and in-cooperative patients.
* Pregnant and lactating women.
* Patients who had motion artifacts, or those who can't stay stable or calm during acquisition.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No